Revolution Medicines Form 4: Goldsmith 10b5-1 Sale Covers RSU Taxes

Rhea-AI Filing Summary

Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, reported a sale of 13,411 shares of the issuer's common stock on 09/16/2025 at a reported price of $45.8249 per share. The filing states the sale was made pursuant to a Rule 10b5-1 instruction letter adopted May 31, 2023 to satisfy the reporting person’s tax withholding obligation upon RSU vesting.

Following the reported transaction, the filing shows 452,309 shares beneficially owned directly, and additional indirect holdings of 20,424, 20,424, and 465,604 shares held by three trusts. The form is signed by an attorney-in-fact on behalf of Mr. Goldsmith.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating pre-established, compliant trading for tax withholding
• Timely disclosure filed on Form 4 and signed by an authorized attorney-in-fact
• Insider retains substantial ownership with combined direct and indirect holdings reported in the filing

Negative

• Reported sale of 13,411 shares reduces the reporting person’s direct holdings
• Price-sensitive transaction could be interpreted by some investors as insider liquidity, though context is provided

Insights

Financial Analyst

TL;DR: Insider sale appears routine tax-withholding under a pre-established 10b5-1 plan and is not an explicit signal of company performance.

The transaction discloses a sale of 13,411 shares at $45.8249 executed under a Rule 10b5-1 plan to satisfy taxes on vested RSUs. Such automated plans are commonly used to avoid timing issues and reduce perception of opportunistic trading. The sale represents a small fraction of the reporting person's combined direct and indirect holdings, which total over 900,000 shares across listed accounts and trusts, so the impact on ownership percentage is limited. No derivative transactions or other compensatory awards are reported on this form.

Corporate Governance Expert

TL;DR: Disclosure demonstrates governance compliance through Rule 10b5-1 execution and timely Section 16 reporting.

The Form 4 clearly states the sale was pursuant to a 10b5-1 instruction adopted May 31, 2023, which supports pre-established, rule-compliant trading. The filing includes detailed indirect ownership via three trusts and is signed by an attorney-in-fact, indicating delegated execution and proper documentation. There are no indications of unusual related-party transfers or sudden changes in compensation structure on this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

GOLDSMITH MARK A

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		S(1)		13,411	D	$45.8249	452,309(2)	D
Common Stock								20,424	I	Trust(3)
Common Stock								20,424	I	Trust(4)
Common Stock								465,604	I	Trust(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 193,475 restricted stock units.

3. Held by Jonathan Goldsmith Revocable Trust.

4. Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.

5. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Remarks:

President and Chief Executive Officer

	/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Mark A. Goldsmith report on Form 4 for Revolution Medicines (RVMD)?

The Form 4 reports a sale of 13,411 common shares on 09/16/2025 at $45.8249 per share by Mark A. Goldsmith.

Why was the sale made according to the Form 4 filing?

The sale was made pursuant to a Rule 10b5-1 instruction adopted May 31, 2023 to satisfy the reporting person’s tax withholding obligation upon RSU vesting.

How many shares does the reporting person beneficially own after the transaction?

The filing shows 452,309 shares beneficially owned directly after the transaction, plus indirect holdings of 20,424, 20,424, and 465,604 in three trusts.

Was any derivative or option transaction reported on this Form 4?

No. The Form 4 contains only non-derivative common stock transactions and does not report any derivative securities.

Who signed the Form 4 and when?

The Form 4 was signed by Jack Anders as attorney-in-fact for Mark A. Goldsmith on 09/18/2025.